SCHEDULE: Perceptive Advisors Discloses 7.6% Stake in X4 Pharma

Perceptive Advisors and its affiliates have reported a 7.6% beneficial ownership stake in X4 Pharmaceuticals, Inc., totaling 6,064,680 shares.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, "Reporting Persons") have filed a Schedule 13G.
• The filing discloses beneficial ownership of 6,064,680 shares of Common Stock in X4 Pharmaceuticals, Inc.
• This represents 7.6% of the Issuer's outstanding Common Stock.
• The ownership percentage is based on 79,214,708 outstanding shares as of October 27, 2025, as described in the Issuer's press release.
• The reported amount includes 5,913,165 directly held shares and 151,515 warrants immediately exercisable by the Master Fund.
• The warrants have an exercise price of $45.00 per share and are subject to a 9.99% beneficial ownership limitation.
• Perceptive Advisors serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing discloses a significant passive ownership stake by a respected life sciences investment firm, which can be interpreted as a vote of confidence in the issuer's prospects. However, it does not contain operational or financial performance updates.

Positives

• A significant stake (7.6%) held by a specialized life sciences investment firm like Perceptive Advisors may signal confidence in X4 Pharmaceuticals' long-term prospects.
• The investment is passive, indicating a belief in the current management and strategy without seeking control.

Risks

• The beneficial ownership of warrants is subject to a 9.99% limitation, restricting the Reporting Persons from exercising warrants if it would exceed this threshold.
• The value of the investment is subject to market fluctuations of X4 Pharmaceuticals' common stock.

Future Outlook

NA

Industry Context

Perceptive Advisors is a well-known investment firm specializing in the life sciences sector. Their significant stake in X4 Pharmaceuticals indicates continued interest and investment in the biotechnology and pharmaceutical industry, particularly in companies with potential for growth or specific therapeutic areas. This type of investment by a specialized fund is common in the biotech space, where long-term capital is often required for drug development.

Comparison to Industry Standards

• Perceptive Advisors is a prominent hedge fund focused on healthcare and life sciences, known for its deep industry expertise. Their investment in X4 Pharmaceuticals aligns with their strategy of identifying promising companies in the biotech sector.
• Similar to other specialized funds like RA Capital Management or Orbimed Advisors, Perceptive often takes significant, but passive, stakes in public biotech companies, providing capital and signaling confidence to the broader market.
• The 7.6% stake is a substantial position, indicating a meaningful commitment to X4 Pharmaceuticals, comparable to other strategic investments seen from major biotech-focused funds in companies like CRISPR Therapeutics or Moderna in their earlier stages of public trading.

Stakeholder Impact

• Shareholders: May view the significant stake by Perceptive Advisors as a positive signal, potentially increasing investor confidence and attracting further investment.
• Management: The passive nature of the investment suggests Perceptive Advisors is supportive of the current management and strategic direction.

Key Dates

Keywords

X4 Pharmaceuticals, Perceptive Advisors, Joseph Edelman, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Biotechnology, Pharmaceuticals, Investment Firm